PMID- 31764835
OWN - NLM
STAT- MEDLINE
DCOM- 20191209
LR  - 20210110
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 98
IP  - 47
DP  - 2019 Nov
TI  - Effects of Gambisan in overweight adults and adults with obesity: A retrospective 
      chart review.
PG  - e18060
LID - 10.1097/MD.0000000000018060 [doi]
LID - e18060
AB  - OBJECTIVE: A retrospective chart review was conducted to explore the effect of 
      Gambisan, a granular extract of novel herbal medicine, for short-term (</=16 weeks) 
      weight loss in adults who are overweight and those with obesity. METHODS: 
      Outpatients of Kyung Hee University Korean Medicine Hospital (Seoul, Korea) who 
      took Gambisan and underwent bioelectric impedance analysis were selected (Jan 
      2011 to Dec 2015); their electronic medical records and clinical charts were 
      retrospectively reviewed. The effectiveness of Gambisan was primarily evaluated 
      by comparing body weight (BW) at baseline and endpoint, using paired t tests; the 
      safety of Gambisan was evaluated on the basis of adverse events (AEs) experienced 
      by patients. RESULTS: Two hundred five patients were included in this study. The 
      study population exhibited a significant reduction in BW (73.69 +/- 14.49 kg to 
      69.01 +/- 13.20 kg, P < .001) as well as percentage body fat (37.38 +/- 5.38% to 
      34.50 +/- 5.83%, P < .001). Moreover, 111 (54.1%) patients achieved modest weight 
      loss (>/=5%), while 35 (17.1%) achieved >/=10% weight loss. Furthermore, Gambisan 
      induced significant reduction of BW in all subgroups (body mass index, sex, 
      prescribed duration, and dosage). Among 139 patients with available data, 79 
      (56.8%) reported loss-of-appetite. In addition, 120 (mostly mild) AEs were 
      reported in 69 (49.6%) patients, and the most frequent AEs were nausea, 
      palpitation, and insomnia. DISCUSSION: Despite limitations in interpreting the 
      results of this retrospective medical record review, Gambisan induced 
      statistically and clinically meaningful weight loss with a tolerable level of 
      AEs. Based on the findings of this review, further well-designed clinical trials 
      are warranted.
FAU - Jo, Dae-Hyun
AU  - Jo DH
AD  - Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee 
      University.
AD  - Department of Korean Medicine, Geumwang Health Subcenter, Bureau of Health 
      Policy, Ministry of Health and Welfare, Seoul, Republic of Korea.
FAU - Lee, Seunghoon
AU  - Lee S
AD  - Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee 
      University.
FAU - Lee, Jae-Dong
AU  - Lee JD
AD  - Department of Acupuncture and Moxibustion, College of Korean Medicine, Kyung Hee 
      University.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Plant Extracts)
RN  - 0 (gambisan)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Obesity/drug therapy
MH  - Overweight/*drug therapy
MH  - *Phytotherapy
MH  - Plant Extracts/*pharmacology/*therapeutic use
MH  - Retrospective Studies
MH  - Time Factors
MH  - Weight Loss/*drug effects
PMC - PMC6882612
COIS- The authors have no conflicts of interests to disclose.
EDAT- 2019/11/26 06:00
MHDA- 2019/12/18 06:00
PMCR- 2019/11/22
CRDT- 2019/11/26 06:00
PHST- 2019/11/26 06:00 [entrez]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2019/12/18 06:00 [medline]
PHST- 2019/11/22 00:00 [pmc-release]
AID - 00005792-201911220-00066 [pii]
AID - MD-D-19-01476 [pii]
AID - 10.1097/MD.0000000000018060 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2019 Nov;98(47):e18060. doi: 10.1097/MD.0000000000018060.